T cell targeting in cancer therapy

SummaryTargeting of immune cells by bispecific antibodies has proven a powerful tool for the investigation of cellular cytotoxicity, lymphocyte activation and induction of cytokine production, as well as to represent an innovative form of immunotherapy for the treatment of cancer. The hallmark of this approach is the use of the specificity of monoclonal antibodies to join target and immune cells by virtue of the dual specificity of bispecific antibodies for the two entities. More precisely the bispecific antibody has two different binding sites, which are capable of recognizing tumor associated antigens on the one hand and lymphocyte activation sites on the other. This process of crosslinking results in the activation of the lymphocyte and triggering of its lytic machinery, as well as lymphokine production. A major advantage of this therapeutic modality is, that use is made of the normal cellular immune defence system and therefore is only associated with minor toxicity. The distinct lymphocyte populations, which can be used for adoptive immunotherapy and the various bispecific antibody preparations, as well as the chimeric immunoglobulin/T cell receptor construction are the major topics of this review.

[1]  C. Janeway,et al.  Coclustering of CD4 (L3T4) molecule with the T-cell receptor is induced by specific direct interaction of helper T cells and antigen-presenting cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Reinherz,et al.  An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein , 1984, Cell.

[3]  B. Bonavida,et al.  Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells. , 1982, Journal of immunology.

[4]  L. Hood,et al.  Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation , 1990, Cell.

[5]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[6]  E. Martz.  Mechanism of specific tumor-cell lysis by alloimmune T lymphocytes: resolution and characterization of discrete steps in the cellular interaction. , 1977, Contemporary topics in immunobiology.

[7]  G. Trinchieri,et al.  The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. , 1984, Journal of immunology.

[8]  T. Springer,et al.  ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells , 1988, Nature.

[9]  B. Fleischer.  Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture , 1984, Nature.

[10]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[11]  J. Parnes.  Molecular biology and function of CD4 and CD8. , 1989, Advances in immunology.

[12]  D. Littman.  The structure of the CD4 and CD8 genes. , 1987, Annual review of immunology.

[13]  L. Lanier,et al.  Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells , 1989, Nature.

[14]  R. Bolhuis,et al.  Phytohemagglutinin-induced proliferation and cytolytic activity in T3+ but not in T3- cloned T lymphocytes requires the involvement of the T3 antigen for signal transmission. , 1985, Cellular immunology.

[15]  M. Caligiuri,et al.  CD3-negative natural killer cells express ε TCR as part of a novel molecular complex , 1989, Nature.

[16]  B. Seed,et al.  Expression and function of CD8 in a murine T cell hybridoma , 1987, Nature.

[17]  P. Marrack,et al.  The antigen-specific, major histocompatibility complex-restricted receptor on T cells. , 1986, Advances in immunology.

[18]  W. White,et al.  Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture , 1983, Cancer Immunology, Immunotherapy.

[19]  G. Berke.  Interaction of cytotoxic T lymphocytes and target cells. , 1980, Progress in allergy.

[20]  K. Cornetta,et al.  Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Segal,et al.  Induction of lysis by T cell receptor gamma delta+/CD3+ T lymphocytes via CD2 requires triggering via the T11.1 epitope only. , 1989, Journal of immunology.

[22]  G. Stoter,et al.  Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. , 1987, Journal of immunology.

[23]  S. Swain.  T Cell Subsets and the Recognition of MHC Class , 1983, Immunological reviews.

[24]  R. Bolhuis,et al.  Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. , 1986, Journal of immunology.

[25]  E. Braakman,et al.  Lymphocyte-mediated responses: activation of, and lysis by, cytotoxic lymphocytes. , 1988, Current opinion in immunology.

[26]  Michael Loran Dustin,et al.  The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. , 1987, Annual review of immunology.

[27]  P. Marrack,et al.  The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody , 1983, The Journal of experimental medicine.

[28]  D. Hafler,et al.  Phosphorylation of CD4 and CD8 molecules following T cell triggering. , 1987, Journal of immunology.

[29]  J. D. de Vries,et al.  Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. , 1988, Journal of immunology.

[30]  M. Caligiuri,et al.  Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Lanier,et al.  Genomic organization of T cell gamma genes in human peripheral blood natural killer cells. , 1986, Journal of immunology.

[32]  J. Seidman,et al.  Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. , 1987, Nature.

[33]  M. Crumpton,et al.  Association of phosphorylation of the T3 antigen with immune activation of T lymphocytes , 1987, Nature.

[34]  R. Bontrop,et al.  Coordinated Vγ and Vδ gene segment rearrangements in human T cell receptor γ/δ+ lymphocytes , 1989 .

[35]  S. Meuer,et al.  Alternative pathway activation of T cells by binding of CD2 to its cell-surface ligand , 1987, Nature.

[36]  C. Morimoto,et al.  Cross-linking of T3 (CD3) with T4 (CD4) enhances the proliferation of resting T lymphocytes. , 1987, Journal of immunology.

[37]  Z. Eshhar,et al.  Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. , 1990, The British journal of cancer. Supplement.

[38]  R. Schmidt,et al.  Activation of Cloned Natural Killer Cells via FcγRIII , 1989 .

[39]  J. Daley,et al.  The T11 (CD2) molecule is functionally linked to the T3/Ti T cell receptor in the majority of T cells. , 1987, Journal of immunology.

[40]  C. Alberini,et al.  Interdependence of CD3‐Ti and CD2 activation pathways in human T lymphocytes. , 1988, The EMBO journal.

[41]  M. Reth,et al.  Molecular components of the B-cell antigen receptor complex of the IgM class , 1990, Nature.

[42]  W. Decock,et al.  Suppression of human T-cell mitogenesis and E-rosette formation by the monoclonal antibody OKT11A. , 1981, Immunology.

[43]  T. Springer,et al.  Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones , 1986, Nature.

[44]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[46]  C. Janeway,et al.  Evidence for a physical association of CD4 and the CD3:alpha:beta T-cell receptor. , 1987, Nature.

[47]  Michael L. Dustin,et al.  T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1 , 1989, Nature.

[48]  S. Ménard,et al.  Anti‐ovarian carcinoma anti‐T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T‐cells , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[49]  C. Janeway,et al.  Evidence for a physical association of CD4 and the CD3: α : β T-cell receptor , 1987, Nature.

[50]  Timothy A. Springer,et al.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.

[51]  R. Schmidt,et al.  Activation of cloned human natural killer cells via Fc gamma RIII. , 1989, Journal of immunology.

[52]  Y. Kurosawa,et al.  Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. , 1987, Biochemical and biophysical research communications.

[53]  L. Hood,et al.  The human t cell antigen receptor is encoded by variable, diversity, and joining gene segments that rearrange to generate a complete V gene , 1984, Cell.

[54]  T. Pozzan,et al.  Antibody-induced modulation of the CD3/T cell receptor complex causes T cell refractoriness by inhibiting the early metabolic steps involved in T cell activation , 1987, The Journal of experimental medicine.

[55]  Mark M. Davis,et al.  Sequence relationships between putative T-cell receptor polypeptides and immunoglobulins , 1984, Nature.

[56]  J. Seidman,et al.  Two forms of the T-cell receptor γ protein found on peripheral blood cytotoxic T lymphocytes , 1987, Nature.

[57]  H. Oettgen,et al.  Characterization of the two heavy chains of the T3 complex on the surface of human T lymphocytes. , 1984, The Journal of biological chemistry.

[58]  M. N. Margolies,et al.  Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice , 1989, Cell.

[59]  M. Rijn,et al.  Alloantigen recognition is preceded by nonspecific adhesion of cytotoxic T cells and target cells. , 1986, Science.

[60]  D. Segal,et al.  Targeting and activation of cytotoxic lymphocytes. , 1989, Chemical immunology.

[61]  J. Yagüe,et al.  Primary structure of human T-cell receptor α-chain , 1984, Nature.

[62]  C. Figdor,et al.  On the mode of action of LFA-1. , 1990, Immunology today.

[63]  P. Hersey,et al.  'Nonspecific' MHC-unrestricted killer cells and their receptors. , 1987, Immunology today.

[64]  B. Bierer,et al.  Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor , 1988, The Journal of experimental medicine.

[65]  J. Bubeník,et al.  Cellular immunity to renal carcinomas in man , 1971, International Journal of Cancer.

[66]  E. Reinherz,et al.  CD2-mediated adhesion facilitates T lymphocyte antigen recognition function , 1989, Nature.

[67]  H. Spits,et al.  Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies. , 1985, Journal of immunology.

[68]  R. Germain,et al.  Specific antigen—la activation of transfected human T cells expressing murine Ti αβ —human T3 receptor complexes , 1987, Nature.

[69]  S. Ratnofsky,et al.  Direct evidence for binding of CD8 to HLA class I antigens , 1989, The Journal of experimental medicine.

[70]  Eric O Long,et al.  CD3-negative lymphokine-activated cytotoxic cells express the CD3 epsilon gene. , 1988, Journal of immunology.

[71]  A. C. Cuello,et al.  Hybrid hybridomas and their use in immunohistochemistry , 1983, Nature.

[72]  J. Seidman,et al.  Identification of a putative second T-cell receptor , 1986, Nature.

[73]  K. Okumura,et al.  Preliminary trial of specific targeting therapy against malignant glioma , 1990, The Lancet.

[74]  C. Cepko,et al.  Construction and applications of a highly transmissible murine retrovirus shuttle vector , 1984, Cell.

[75]  R. Schmidt,et al.  Characteristics and uses of natural killer cells. , 1988, Immunology today.

[76]  G. Fleuren,et al.  Induction of tumor‐cell lysis by bi‐specific monoclonal antibodies recognizing renal‐cell carcinoma and cd3 antigen , 1989, International journal of cancer.

[77]  J. Ritz,et al.  Characterization of functional surface structures on human natural killer cells. , 1988, Advances in immunology.

[78]  G. Fleuren,et al.  Bispecific antibodies reactive with the multidrug‐resistance‐related glycoprotein and CD3 induce lysis of multidrug‐resistant tumor cells , 1989, International journal of cancer.

[79]  J. Hansen,et al.  Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen) , 1985, The Journal of experimental medicine.

[80]  J. C. Pratt,et al.  Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein , 1985, Nature.

[81]  Colgan P. Sean.  Cell-Cell Interactions , 2006, Methods in Molecular Biology™.

[82]  D. Segal,et al.  Lymphocyte leukocyte function-associated antigen 1 interacting with target cell intercellular adhesion molecule 1 co-activates cytolysis triggered via CD16 or the receptor involved in major histocompatibility antigen-unrestricted lysis. , 1990, International immunology.

[83]  S. Herrmann,et al.  CTL adhesion and antigen recognition are discrete steps in the human CTL-target cell interaction. , 1987, Journal of immunology.

[84]  J. McCubrey,et al.  Transfer of specificity by murine α and β T-cell receptor genes , 1986, Nature.

[85]  G. Trinchieri,et al.  Response of resting human peripheral blood natural killer cells to interleukin 2 , 1984, The Journal of experimental medicine.

[86]  D. Segal,et al.  Icam ‐ melanoma cells are relatively resistant to cd3‐mediated t‐cell lysis , 1990, International journal of cancer.

[87]  J. D. de Vries,et al.  The role of T8 in the cytotoxic activity of cloned cytotoxic T lymphocyte lines specific for class II and class I major histocompatibility complex antigens. , 1985, Journal of immunology.

[88]  D. Stephany,et al.  Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies , 1984, The Journal of experimental medicine.

[89]  B. Bonavida,et al.  Studies on the mechanism of natural killer cytotoxicity. II. coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells. , 1983, Journal of immunology.

[90]  J. Seidman,et al.  A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes , 1987, Nature.

[91]  Michael Loran Dustin,et al.  Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1 , 1989, Nature.

[92]  R. Demars,et al.  Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. , 1990, Science.

[93]  Michael Loran Dustin,et al.  The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3 , 1987, Nature.

[94]  H. Spits,et al.  Analysis of antigen specificity of human TCR gamma delta + T cells. , 1990, Research in immunology.

[95]  E. Braakman,et al.  Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells. , 1990, Journal of immunology.

[96]  D. Segal,et al.  Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. , 1987, Journal of immunology.

[97]  E. Reinherz,et al.  Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[98]  J. Ortaldo,et al.  Heterogeneity of natural killer cells. , 1984, Annual review of immunology.

[99]  F. Burnet.  The concept of immunological surveillance. , 1970, Progress in experimental tumor research.

[100]  Eric O Long,et al.  Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen , 1987, Nature.

[101]  G. Trinchieri,et al.  Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells , 1988, The Journal of experimental medicine.

[102]  P. Lydyard,et al.  Use of the ELISA to screen for anti-thymocyte and anti-beta 2-microglobulin antibodies in leprosy and SLE. , 1980, Immunology.

[103]  M. Crumpton,et al.  The CD2 antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface of human T lymphocytes , 1989, Nature.

[104]  J. Strominger,et al.  Cross-linking of human T cell receptor proteins: association between the T cell idiotype β subunit and the T3 glycoprotein heavy subunit , 1985, Cell.

[105]  J. D. Young,et al.  Multiple mechanisms of lymphocyte-mediated killing. , 1988, Immunology today.

[106]  A. Lesk,et al.  The outline structure of the T‐cell alpha beta receptor. , 1988, The EMBO journal.

[107]  B. V. van Krimpen,et al.  Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1. , 1987, Journal of immunology.

[108]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[109]  F. Sánchez‐Madrid,et al.  The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. , 1983, Journal of immunology.

[110]  Tak W. Mak,et al.  A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains , 1984, Nature.

[111]  E. Gilboa,et al.  An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. , 1991, Science.

[112]  Z. Eshhar,et al.  Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. , 1989, Transplantation proceedings.

[113]  Mark M. Davis,et al.  T-cell antigen receptor genes and T-cell recognition , 1988, Nature.

[114]  Susumu Tonegawa,et al.  Junctional sequences of T cell receptor γδ genes: Implications for γδ T cell lineages and for a novel intermediate of V-(D)-J joining , 1989, Cell.

[115]  N. Abraham,et al.  Enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck , 1991, Nature.

[116]  A. Lanzavecchia,et al.  The use of hybrid hybridomas to target human cytotoxic T lymphocytes , 1987, European journal of immunology.